Silexion Therapeutics Corp, a Cayman Islands company with Ordinary Shares and warrants listed on The Nasdaq Stock Market, reported a change in its Board of Directors. On July 30, 2026, Professor Amnon Peled notified the Board of his resignation as a director.
His resignation is for personal reasons and will be effective as of August 1, 2026. The company reports that his decision did not arise from any disagreement with Silexion regarding its operations, policies, or practices.
Silexion Therapeutics Corp. announced the successful initiation of its Phase 2/3 clinical trial of SIL204, a small interfering RNA (siRNA) candidate, in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, formally activating the first clinical site and clearing it to begin patient screening, with first dosing anticipated afterward.
The trial evaluates SIL204 plus standard-of-care chemotherapy using a dual-route strategy that combines intratumoral delivery to overcome stromal barriers with systemic administration to address metastatic disease. It begins with an initial safety run-in of approximately 18 patients, then expands globally to a randomized cohort of approximately 166 patients. SIL204 is designed to silence a broad range of KRAS mutations, which occur in about 90% of pancreatic cancers, 45% of colorectal cancers, and 30–35% of lung adenocarcinomas, supporting potential use across multiple KRAS-driven tumors.
Silexion Therapeutics Corp reported that at its reconvened extraordinary general meeting on July 20, 2026, shareholders approved changes affecting warrants and share capital. The meeting initially lacked a standard quorum, but under the company’s articles, shareholders present after a half hour constituted a valid quorum.
Holders of 230,276 ordinary shares, representing 21.7% of issued and outstanding ordinary shares, were present in person or by proxy. A New Warrant Exercisability Proposal passed with 214,091 votes (93.3%) in favor and 15,293 against. An Authorized Share Capital Increase Proposal passed with 205,551 votes (89.8%) in favor and 23,382 against. The associated Memorandum Amendment, which increases authorized share capital, became effective when filed in the Cayman Islands on July 21, 2026.
Silexion Therapeutics Corp’s major holder has updated its ownership report. Moringa Sponsor, Moringa Partners Ltd and Ilan Levin together report beneficial ownership of 199,053 ordinary shares, representing 10.6% of Silexion’s ordinary shares, based on 1,877,696 shares outstanding as disclosed in a Form S‑3.
The filing details share issuances of 45,000, 92,500 and 60,819 ordinary shares that Silexion reported as issued to Moringa Sponsor upon conversion of an Amended and Restated Promissory Note originally totaling $3.4 million, including conversions of $1.8 million and two tranches of $0.4 million each. The reporting persons state they dispute the validity of these particular share issuances and do not concede beneficial ownership of those shares, and they characterize this amendment as being filed out of an abundance of caution.
Silexion Therapeutics Corp is calling an extraordinary general meeting on July 13, 2026 to seek shareholder approval for two capital-related proposals tied to its Nasdaq listing and clinical funding needs.
The first proposal asks shareholders to approve the exercisability of 399,020 new Series C and D warrants at $5.00 per share and 13,966 placement agent warrants at $6.25 per share that were issued in a May 18, 2026 warrant inducement financing which raised about $1.0 million and helped restore compliance with Nasdaq’s $2.5 million shareholders’ equity requirement.
The second proposal would increase authorized share capital by 10,000,000 ordinary shares to a total of 15,900,000 shares, giving Silexion more capacity to issue equity for financings, operations and potential business development while maintaining its Nasdaq Capital Market listing as it begins Phase 2/3 trials for SIL‑204.
Silexion Therapeutics Corp files a shelf registration to register the resale by selling shareholders of up to 859,609 ordinary shares, comprising up to 399,020 shares issuable upon new warrants, 13,966 placement agent warrant shares and up to 446,623 shares issuable upon conversion of the Sponsor Promissory Note.
The prospectus states the company will receive no proceeds from sales by the selling shareholders, though it may receive cash proceeds if warrants are exercised for cash. The filing discloses recent financings (an inducement warrant exercise raising ~$1.0M, ATM sales of ~$1.75M net aggregate through June 10, 2026), a 1-for-10 reverse split in May 2026, restored Nasdaq shareholders' equity compliance above the $2.5M minimum, and ongoing Nasdaq monitoring until September 23, 2026.
Silexion Therapeutics Corp reported that CSO and CDO Shirvan Mitchell received a grant of 6,000 Ordinary Shares via fully vested restricted share units, settled immediately in respect of his services as an officer and approved by the board of directors. Following this grant, he directly holds 8,789 Ordinary Shares.
The filing also updates option holdings after a 1-for-10 reverse share split effective on May 28, 2026. Mitchell now holds options to purchase 48 Ordinary Shares at an exercise price of $9,077.10 per share, expiring on June 7, 2032.
Horenshtein Hadar Mirit reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp reported that its CFO and Secretary, Hadar Mirit Horenshtein, received a grant of 7,500 fully vested restricted share units that were immediately settled into ordinary shares, at a stated price of $0.00 per share, for service as an officer. Following this award, the reporting person directly holds 12,515 ordinary shares. A prior 1-for-10 reverse share split on May 28, 2026 adjusted earlier beneficial holdings from 50,146 ordinary shares at $0.0135 par value to 5,015 ordinary shares at $0.135 par value before this grant.
Silexion Therapeutics Corp reported that Chairman and CEO Hadar Ilan received a grant of 10,000 ordinary shares at no cost, delivered through fully vested restricted share units for services as an officer and approved by the board. After this award, Ilan directly holds 16,547 ordinary shares. The Form 4 also updates a stock option position to 96 options for 96 ordinary shares at an exercise price of $9,077.10 per share, reflecting a 1-for-10 reverse share split completed on May 28, 2026. The option holdings are shown for informational purposes, with no new option transactions reported.
Moringa Sponsor, LP and related parties filed Amendment No. 2 to their Schedule 13D on Silexion Therapeutics Corp. They report beneficial ownership of 1,382,346 ordinary shares, representing 32.99% of Silexion’s ordinary shares outstanding, calculated using 4,189,954 shares reported in Silexion’s Form 10-Q as of March 31, 2026.
The reported holdings include 6,970 ordinary shares, 372 ordinary shares underlying warrants, 450,000 ordinary shares issued on September 15, 2025 upon conversion of $1.8 million under an Amended and Restated Promissory Note, and 925,004 ordinary shares issued on May 14, 2026 upon conversion of $0.4 million under the same note. The reporting persons state they are filing out of an abundance of caution and expressly dispute the validity of the 450,000 and 925,004 shares and do not concede beneficial ownership of them.